Tanvex BioPharma Inc., the biosimilar-focused biopharmaceutical company and CDMO, has appointed Stephen Lam as its Chief Executive Officer, effective September 5, 2024.
 
Lam succeeds Henry Chen, who will remain the Chairman until the closing of Tanvex’s strategic alliance with Bora Pharmaceuticals Co., Ltd.
​
As a part of the new leadership initiated by Bora, Lam will be responsible for ensuring a successful integration, driving the Company’s strategic initiatives as well as overseeing Tanvex’s day-to-day operations, including its global CDMO operations and the commercialization of its biosimilar pipeline.
 
With over 35 years in the biopharmaceutical industry at leading companies including Lonza, Amgen, and Patheon, Lam has built a strong track record of delivering results. Most recently, he served as Vice President and General Manager, Head of Biologics at Thermo Fisher Scientific.
​​
“I am honored to take on the role of CEO at Tanvex. By integrating Tanvex’s established commercial biologics manufacturing with Bora’s strong reputation, industry leading quality, and proven process development expertise,” said Lam, “We can serve our customers no matter where they are in their drug development lifecycle, from First-In-Human studies through to commercial launch.”